Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
View ORCID ProfileNatalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, View ORCID ProfileAnne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
doi: https://doi.org/10.1101/2022.05.06.22274690
Natalia Martin Orozco
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
PhDNoah Vale
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
MDAlan Mihic
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
MDTalya Amor
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
BScLawrence Reiter
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
PhDYuko Arita
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
PhDReuben Samson
cDepartment of Molecular Genetics, University of Toronto. 1 King’s College Cir, Rm 4396, Toronto, ON, M5S 1A8, Canada
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
BScQueenie Hu
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
PhDAnne-Claude Gingras
cDepartment of Molecular Genetics, University of Toronto. 1 King’s College Cir, Rm 4396, Toronto, ON, M5S 1A8, Canada
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
PhDBrad Sorenson
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
BScEric G. Marcusson
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
PhDPiyush Patel
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
MDData Availability
All data produced in the present work are contained in the manuscript.The development of the B.1.617.2 (Delta) lentiviral assay was supported by the CIHR operating grant to the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to A.-C.G. A.-C.G. is the Canada Research Chair, Tier 1, in Functional Proteomics.
Posted May 10, 2022.
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Natalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, Anne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
medRxiv 2022.05.06.22274690; doi: https://doi.org/10.1101/2022.05.06.22274690
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Natalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, Anne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
medRxiv 2022.05.06.22274690; doi: https://doi.org/10.1101/2022.05.06.22274690
Subject Area
Subject Areas
- Addiction Medicine (390)
- Allergy and Immunology (705)
- Anesthesia (196)
- Cardiovascular Medicine (2877)
- Dermatology (245)
- Emergency Medicine (432)
- Epidemiology (12604)
- Forensic Medicine (10)
- Gastroenterology (811)
- Genetic and Genomic Medicine (4476)
- Geriatric Medicine (407)
- Health Economics (717)
- Health Informatics (2867)
- Health Policy (1057)
- Hematology (378)
- HIV/AIDS (907)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (465)
- Neurology (4233)
- Nursing (226)
- Nutrition (620)
- Oncology (2218)
- Ophthalmology (631)
- Orthopedics (255)
- Otolaryngology (322)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (489)
- Pediatrics (1182)
- Primary Care Research (485)
- Public and Global Health (6819)
- Radiology and Imaging (1502)
- Respiratory Medicine (907)
- Rheumatology (430)
- Sports Medicine (373)
- Surgery (475)
- Toxicology (59)
- Transplantation (204)
- Urology (175)